Cyclacel Stock Valuation

CYCC
 Stock
  

USD 0.83  0.04  4.60%   

Do you wonder what the value of Cyclacel Pharmaceuticals is? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Cyclacel Pharmaceuticals, is its stock price multiplied by the total number of shares outstanding, calculating Cyclacel Pharmaceuticals' enterprise value requires a different approach. It uses Cyclacel Pharmaceuticals' balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
Cyclacel Pharmaceuticals shows a prevailing Real Value of $5.61 per share. The current price of the firm is $0.83. Today, the firm appears to be undervalued. Our model approximates the value of Cyclacel Pharmaceuticals from analyzing the firm fundamentals such as return on equity of (0.60) %, and Current Valuation of (13.12 M) as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor taking in undervalued instruments and trading overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
  
Cyclacel Pharmaceuticals Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Cyclacel Pharmaceuticals's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.

Cyclacel Most Recent Valuation Data

Beta
1.13
Fiscal Year End
December
property Plant And Equipment Net
94 K
Enterprise Value
-13.1 M
net Debt
-36.6 M
accounts Payable
2.1 M
Undervalued
Today 0.83
Please note that Cyclacel Pharmaceuticals' price fluctuation is relatively risky at this time. Calculation of the real value of Cyclacel Pharmaceuticals is based on 3 months time horizon. Increasing Cyclacel Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Cyclacel Pharmaceuticals is useful when determining the fair value of the Cyclacel stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Cyclacel Pharmaceuticals. Since Cyclacel Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cyclacel Stock. However, Cyclacel Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
5.61
Real Value
10.64
Upside
Estimating the potential upside or downside of Cyclacel Pharmaceuticals helps investors to forecast how Cyclacel stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cyclacel Pharmaceuticals more accurately as focusing exclusively on Cyclacel Pharmaceuticals' fundamentals will not take into account other important factors:
Earnings
Estimates (3)
LowProjected EPSHigh
-2.33-2.27-2.24
Details
Hype
Prediction
LowEstimated ValueHigh
0.040.835.86
Details
4 Analysts
Consensus
LowTarget PriceHigh
17.0020.0024.00
Details

Cyclacel Pharmaceuticals Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Cyclacel Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Cyclacel Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cyclacel Pharmaceuticals competition to find correlations between indicators driving Cyclacel Pharmaceuticals's intrinsic value. More Info.
Cyclacel Pharmaceuticals is rated third in beta category among related companies. It is number one stock in price to sales category among related companies fabricating about  65.72  of Price to Sales per Beta. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Cyclacel Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cyclacel Pharmaceuticals' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cyclacel Pharmaceuticals' earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Cyclacel Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Cyclacel Pharmaceuticals and how it compares across the competition.

About Cyclacel Pharmaceuticals Valuation

The stock valuation mechanism determines the current worth of Cyclacel Pharmaceuticals on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Cyclacel Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Cyclacel Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Cyclacel Pharmaceuticals's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Cyclacel Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cyclacel Pharmaceuticals. We calculate exposure to Cyclacel Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Cyclacel Pharmaceuticals's related companies.
Fiscal Year End
December
Industry
Biotechnology
Concentration
Biotechnology
Service Category
Biotechnology
Employer Id Number
91-1707622
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuti operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
Continue to Trending Equities. Note that the Cyclacel Pharmaceuticals information on this page should be used as a complementary analysis to other Cyclacel Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Complementary Tools for Cyclacel Stock analysis

When running Cyclacel Pharmaceuticals price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Is Cyclacel Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
9.6 M
Return On Assets
(0.42) 
Return On Equity
(0.60) 
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Cyclacel Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.